XLKG(SZ:000955)2020-04-29 16:00Revenue and Profit - Revenue for Q1 2020 reached ¥290,689,569.18, an increase of 30.04% compared to ¥223,546,155.81 in the same period last year[7] - Net profit attributable to shareholders was ¥58,353,666.86, a significant increase of 1,545.49% from ¥3,546,287.22 year-on-year[7] - Net profit excluding non-recurring items was ¥57,520,394.28, up 39,720.30% from ¥144,449.94 in the previous year[7] - The company's operating revenue increased by 30.04% year-on-year, reaching ¥290,689,569.18, driven by heightened demand for medical protective materials[15] - Net profit for Q1 2020 was CNY 75,794,670.25, significantly up from CNY 2,786,803.02 in the same period last year, marking an increase of over 2600%[38] - The company reported a significant increase in minority interest profit to CNY 17,441,003.39 from a loss of CNY 759,484.20 in the previous year[38] Cash Flow and Financial Position - Operating cash flow for the period was ¥54,775,675.30, a turnaround from a negative cash flow of -¥27,687,158.94, representing a 297.84% improvement[7] - The net cash inflow from operating activities surged by 297.84%, amounting to ¥54,775,675.30, due to increased sales collections[16] - Cash flow from operating activities generated a net inflow of ¥54,775,675.30, contrasting with a net outflow of -¥27,687,158.94 in the prior period[43] - Cash and cash equivalents at the end of the period totaled ¥264,348,464.49, down from ¥374,361,131.84 at the end of the previous period[44] - The total cash and cash equivalents at the end of the first quarter were 140,992,708.10 CNY, an increase from the beginning balance of 39,051,055.37 CNY[47] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,301,687,184.15, reflecting a 9.31% increase from ¥1,190,778,578.72 at the end of the previous year[7] - The company's total assets as of March 31, 2020, were CNY 1,065,547,988.05, compared to CNY 1,046,970,907.99 at the end of 2019, reflecting a slight increase[34] - The total liabilities increased to CNY 385,704,824.61 from CNY 365,673,984.87, indicating a rise of approximately 5%[34] - Total current liabilities rose to CNY 455,985,360.62 from CNY 321,531,800.14, reflecting an increase of about 42.0%[30] - The total liabilities increased to CNY 587,906,668.82 from CNY 552,882,733.64, indicating a growth of approximately 6.3%[30] Shareholder Information - The company reported a total of 96,194 common shareholders at the end of the reporting period[10] - The top shareholder, Jiaxing Tiantang Silicon Valley Equity Investment Co., Ltd., held 9.24% of shares, totaling 49,760,810 shares[10] - The company's equity attributable to shareholders was CNY 672,277,513.12, up from CNY 613,923,846.26, representing an increase of about 9.5%[34] Research and Development - Research and development expenses soared by 343.72% to ¥2,759,559.80, reflecting increased investment in medical protective material development[15] - Research and development expenses increased to CNY 2,759,559.80 from CNY 621,912.96, indicating a rise of over 300%[37] Other Financial Metrics - Basic earnings per share increased to ¥0.1084, a rise of 1,542.42% from ¥0.0066 in the same quarter last year[7] - The weighted average return on equity was 9.07%, a significant increase from 0.57% in the previous year[7] - The company's cash and cash equivalents decreased by 85.67% to ¥26,091,558.78, primarily due to a reduction in net bank borrowings compared to the previous period[16] - The company's short-term borrowings rose by 122.61%, totaling ¥257,870,083.38, attributed to an increase in one-year bank loans[15] - The company's profit tax expenses skyrocketed by 2366.06% to ¥6,325,026.83, mainly due to increased profitability[16] - The company's financial expenses decreased by 9.85% to ¥5,688,543.62, primarily due to increased exchange gains[15]